Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BS-006 in Recurrent Cervical Cancer
NCT05393440Phase 1Unknown
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BS-006 in Cervical Cancer (CC) (2 cohorts), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoints: Maximal Tolerable Dose at 2 months, Rate and Grade of Adverse Events and 1 more. Status: unknown.
02
Drugs
BS-006
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05393440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393440.